Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 10/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.48 |
| ▸ | TSG101 | Q99816 | 5/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13754061 | 0.98 | NAALAD2 (0.52) | NAALAD2PRMT5WDR77TSG101NR1H2 | |
| SCHEMBL14262326 | 0.83 | PRMT5 (0.46) | NAALAD2PRMT5WDR77TSG101NR1H2 | |
| SCHEMBL10060515 | 0.82 | PRMT5 (0.46) | NAALAD2PRMT5WDR77TSG101NR1H2 | |
| SCHEMBL13747486 | 0.82 | PRMT5 (0.46) | NAALAD2PRMT5WDR77TSG101NR1H2 | |
| SCHEMBL13203414 | 0.81 | PRMT5 (0.46) | NAALAD2PRMT5WDR77TSG101NR1H2 | |
| SCHEMBL13164737 | 0.76 | PRMT5 (0.42) | NAALAD2PRMT5WDR77TSG101NR1H2 | |
| SCHEMBL10060330 | 0.76 | PRMT5 (0.44) | NAALAD2PRMT5WDR77TSG101NR1H2 | |
| SCHEMBL11952927 | 0.76 | PRMT5 (0.44) | NAALAD2PRMT5WDR77TSG101NR1H2 | |
| SCHEMBL19365089 | 0.75 | TSG101 (0.56) | NAALAD2PRMT5WDR77TSG101 | |
| SCHEMBL15828661 | 0.75 | TSG101 (0.55) | NAALAD2PRMT5WDR77TSG101 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080069812-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents | AEGERA THERAPEUTICS, INC. (CA) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080069812-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents | BIRC5, XIAP, BIRC2 | NAALAD2 2239/4885PRMT5 1188/4885WDR77 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.